A Mental Health Lifeline: How Psychedelics Could Offer Millions of Americans Hope

On October 8, 2025, Stanford neuroscientist Nolan Williams—a pioneer of rapid-acting treatments for severe depression—died by suicide at age 42. His premature death, and the profound loss it represents, underscores the urgency that drove his work: the need for fast-acting, effective treatment options for individuals experiencing acute mental health crises, particularly those enduring chronic and severe suffering. For patients who have exhausted evidence-based therapies—including selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, and cognitive behavioral interventions—access to experimental treatments should be no less available than it is for individuals with refractory cancer or Parkinson’s disease.

Psychedelic therapies are emerging as promising candidates across a range of psychiatric conditions,¹ including major depressive disorder, treatment-resistant depression, post-traumatic stress disorder, obsessive-compulsive disorder, and substance use disorders. Several compounds—such as lysergic acid diethylamide (LSD), ^3,4-methylenedioxymethamphetamine (MDMA), and psilocybin—have received Breakthrough Therapy designation from the US Food and Drug Administration (FDA). This designation is designed to accelerate the development and review of drugs that target serious conditions where preliminary research suggests the drug may demonstrate meaningful improvements over existing therapies on clinically significant endpoint measures.

Psychedelic medicines, particularly offered in the context of psychotherapy, may offer several advantages over existing treatments for mental health. First, and most notably, therapeutic effects—when present—often occur rapidly. Across clinical trials, symptom improvement is frequently observed during the first post-dosing assessment.^2-4 By contrast, SSRIs may require weeks or months to produce benefit, and many patients cycle through multiple medications titrations before achieving relief.⁵ Under highly acute conditions, clinicians may recommend first- and second-generation antipsychotics or benzodiazepines for more rapid symptom management for severe depression or anxiety, despite their well-documented risks, including metabolic complications (antipsychotics) and potential for dependence (benzodiazepines).

Second, the side-effect profiles of psychedelic therapies appear to be largely transient.^6,7 While acute administration can involve increases in heart rate and blood pressure, changes in thermoregulation, and periods of psychological distress such as anxiety or agitation, these effects typically resolve as the drug is metabolized. Importantly, these sessions are conducted with psychological support and medical monitoring. In contrast, chronic adverse effects from conventional psychotropic medications are a leading cause of treatment discontinuation and non-adherence.⁸

Third, psychedelic treatments are typically administered in one or a limited number of supervised sessions, rather than as continuous daily regimens. This model addresses a common concern with existing pharmacotherapies—the absence of a clear “off-ramp.” Even after symptom improvement, patients are often advised to continue medications indefinitely to prevent relapse, thereby prolonging exposure to side effects that may persist for years.

Finally, psychedelics may enhance, rather than blunt, emotional processing. In contrast to medications that dampen affect, these compounds can facilitate emotionally salient experiences that, when combined with psychotherapy, may strengthen the therapeutic alliance and create opportunities for durable cognitive and behavioral change. This capacity to “open a window” for learning and psychological flexibility may increase both the efficacy and efficiency of psychotherapy.

Despite these promising attributes, regulatory barriers limit access. The 2018 Right to Try Act allows terminally ill patients ineligible for clinical trials to access investigational therapies that have completed Phase I testing, provided manufacturers are willing to supply them. This pathway has offered hope to patients and has generated real-world data on treatment effects in more complex clinical populations. However, the Act does not override the Controlled Substances Act (CSA), which classifies psychedelics—and cannabis—as Schedule I substances, defined as having no accepted medical use and a high potential for abuse. This classification has created regulatory inconsistencies, particularly as cannabis is now legal in many states, and has significantly constrained psychedelic research and access.

As Schedule I designation has slowed the pace of research, particularly federally funded research, states and local jurisdictions have responded to pressure from voters to develop alternative access pathways. Oregon, Colorado, and more recently New Mexico have established legal frameworks for supervised adult use of psychedelics, most commonly psilocybin. While these programs expand access, they also introduce important limitations. In Oregon, for example, licensed clinicians must operate outside the scope of their professional licenses during dosing sessions, serving as facilitators rather than health care providers, despite being fully qualified to provide preparatory and integration therapy. Practicing outside of scope is a vulnerability that may deter participation in the practice. Although early data suggest that supervised psilocybin use in these settings is relatively low-risk, it is estimated over 11,000 individuals have participated with a trivial percentage reporting serious adverse experiences, these models do not fully replicate the safeguards or therapeutic structure of clinical trials or clinical practice. As a result, individuals may receive psychedelic substances in less regulated environments and without comprehensive medical or psychiatric evaluation. This is particularly concerning for higher-risk or complex patients who would benefit most from integrated clinical care.

In Colorado, practitioners can receive special licensure to offer approved plant medicines, but without FDA approval these treatments are not covered by insurance, and are thus financial untenable for many people. New Mexico’s Medical Psilocybin Act represents a more clinically grounded approach, restricting use to health care settings. However, these services remain outside FDA approval pathways and also will not likely be covered by insurance, limiting equitable access. More broadly, the divergence between public demand, driven in part by growing evidence and patient advocacy, and the pace of federal regulatory processes has created a fragmented system. Because Schedule I status excludes psychedelics from Expanded Access and most compassionate use programs, patients are increasingly seeking care in settings designed for “wellness” rather than medical treatment.

Recent legislative efforts suggest a potential pathway to reconcile federal policy with emerging scientific evidence and patient need. In the 119th Congress, a bipartisan bill (S. 3346), sponsored by Senators Cory Booker and Rand Paul, proposes to “establish a special registration under the Controlled Substances Act for Schedule I eligible investigational drugs under the Federal Right to Try Act.” Titled the Freedom to Heal Act of 2025, the legislation would permit qualified physicians to apply to the Attorney General for authorization to administer Schedule I investigational drugs to eligible patients, contingent upon the cooperation of the drug manufacturer or sponsor.

Importantly, the bill incorporates a number of safeguards, including requirements for clinician training, patient monitoring, and documentation supporting the appropriateness of treatment. These provisions aim to balance expanded access with patient safety and clinical accountability—addressing a longstanding concern that loosening restrictions on Schedule I substances could outpace the development of appropriate medical infrastructure.

If enacted, this policy would move the United States closer to international models that have already expanded regulated access to psychedelic therapies. In Canada, for example, Health Canada’s Special Access Program (SAP) has enabled patients with serious or life-threatening conditions to receive otherwise restricted treatments, including psychedelic-assisted therapies. The agency has explicitly identified indications such as end-of-life distress and treatment-resistant depression as eligible for psilocybin therapy, and post-traumatic stress disorder for MDMA-assisted treatment. As a result, a growing number of Canadian patients have accessed these interventions within a regulated medical framework, generating both clinical benefit and real-world evidence.⁹

This month, President Donald Trump signed an executive order signaling the administration’s interest in removing existing regulatory barriers for psychedelic research and compassionate use through the Federal Right to Try Act. Additionally, it encourages the FDA to grant National Priority Vouchers to eligible psychedelic drugs that have received Breakthrough Therapy designations for mental health conditions. The Order directs $50 million towards Advanced Research Projects for Health (ARPA-H) research, likely funding ibogaine research in Texas. Lastly, the order instructs an expedited rescheduling process for molecules that have successfully completed Phase 3 clinical trials, to accelerate access post-FDA approval.

The urgency of expanding access to effective mental health interventions cannot be overstated. Suicide is the second leading cause of death among Americans aged 10-44, reflecting a persistent and deeply consequential gap in treatment efficacy and accessibility. Framing mental health conditions as less urgent or less deserving of innovative therapeutic options than somatic illnesses, such as cancer, fails to recognize the life-threatening and life-altering nature of disorders including major depression, severe anxiety, and end-of-life psychological distress.

A policy framework that enables carefully regulated, evidence-informed access to investigational psychedelic therapies would not only align with emerging science but also affirm a broader commitment to equity in how we prioritize and respond to human suffering.

References

About the Author